Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.The company was founded in 2018 and is based in Solana Beach, California, United States.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 7, 2022 | Series B | $101M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Piper Heartland Healthcare Capital | — | Series B |